


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<div style="text-align: center;">  <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p> </div>				Complete if Known	
				Application Number	10/788,478
				Filing Date	March 1, 2004
				First Named Inventor	Jean-Pierre Julien
				Art Unit	
				Examiner Name	
Sheet	1	of	4	Attorney Docket Number	1770-300US-1 VC/dm


[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A/B 08-03)

Approved for use through 07/31/2008. OMB 0651-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/788,478		
		Filing Date	March 1, 2004		
		First Named Inventor	Jean-Pierre Julien		
		Art Unit	1614		
Sheet	2	of	4	Examiner Name	SPINACK
				Attorney Docket Number	1770-300US-1 VC/dm

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
PS		BEAULIEU, J.M. et al., "Induction of Peripherin Expression in Subsets of Brain Neurons After Lesion Injury or Cerebral Ischemia", Brain.Res. (2002) 946, 153-161 -	
		BENSIMON, G. et al., "A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis", N. Eng. J. Med. (1994) 330, 585-591 -	
		CANO-ABAD, M.F. et al., "Calcium Entry Through L-type Calcium Channels Causes Mitochondrial Disruption and Chromaffin Cell Death", J. Biol. Chem. (2001) 43, 39695-39704 -	
		CHEN, M. et al., "Minocycline Inhibits Caspase-1 and Caspase-3 Expression and Delays Mortality in a Transgenic Mouse Model of Huntington Disease", Nat. Med. (2000) 6, 797-801.	
		ROGERS, D.C. et al., "Behavioral and Functional Analysis of Mouse Phenotype: SHIRPA, a Proposed Protocol for Comprehensive Phenotype Assessment", Mammalian Genome (1997) 8, 711-713 .	
		ROGERS, D.C. et al., "Use of SHIRPA and Discriminant Analysis to Characterise Marked Differences in the Behavioural Phenotype of Six Inbred Mouse Strains", Behav. Brain Res. (1999) 105, 207-217.	
		DERESKI, M.O. et al., "The Heterogeneous Temporal Evolution of Focal Ischemia Neuronal Damage in the Rat", Acta Neuropathol. (1993) 85, 327-333.	
		DIRNAGL, U. et al., "Pathobiology of Ischaemic Stroke: An Integrated View", Trends Neurosci. (1999) 22, 391-397.	
		DU, Y. et al., "Minocycline Prevents Nigrostriatal Dopaminergic Neurodegeneration in the MPTP Model of Parkinson's Disease", Proc. Natl. Acad. Sci. (2001) 98, 14669-14674.	
		GOLUB, L.M. et al., "Tetracyclines Inhibit Connective Tissue Breakdown by Multiple Non-Antimicrobial Mechanisms", Adv. Dent. Res. (1998) 12, 12-26 .	

Examiner Signature	P. Spivack	Date Considered	7/24/05
--------------------	------------	-----------------	---------

*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/788,478	
			Filing Date	March 1, 2004	
			First Named Inventor	Jean-Pierre Julien	
			Art Unit		
			Examiner Name	SPINACK	
Sheet	3	of	4	Attorney Docket Number	1770-30003-1 VC/dm

13	GOULDEN, V. et al., "Safety of Long-Term High-Dose Minocycline in the Treatment of Acne", Br. J. Dermatol. (1996) 134, 693-695.
	GURNEY, M.E. et al., "Benefit of Vitamin E, Riluzole, and Gabapentin in a Transgenic Model of Familial Amyotrophic Lateral Sclerosis", Ann. Neurol. (1996) 39, 147-157.
	HACKE, W. et al., "Thrombolysis in Acute Ischemic Stroke: Controlled Trials and Clinical Experience", Neurology (1999) 53, S3-14.
	JULIEN, J.P., "Amyotrophic Lateral Sclerosis: Unfolding the Toxicity of the Misfolded", Cell (2001) 104, 581-591.
	KORENKOV, A.I. et al., "Treatment with Nimodipine or Mannitol Reduces Programmed Cell Death and Infarct Size Following Focal Cerebral Ischemia", Neurosurg. Rev. (2000) 23, 145-150.
	KRIZ J. et al., "Differential Effects of Dihydropyridine Calcium Channel Blockers in Kainic Acid-Induced Experimental Seizures in Rats", Epilepsy Res. (2003) 52, 215-225.
	KRIZ, J. et al., "Efficient Three-Drug Cocktail for Disease Induced by Mutant Superoxide Dismutase", Ann. Neurol. (2003) 53, 429-436.
	KRIZ, J. et al., "Minocycline Slows Disease Progression in a Mouse Model of Amyotrophic Lateral Sclerosis", Neurobiol. Dis. (2002) 10, 268-278.
	LO, E.H. et al., "Mechanisms, Challenges and Opportunities in Stroke", Nat. Rev. Neurosci. (2003) 4, 399-415.
	MARTIN, D. et al., "The Neuroprotective Agent Riluzole Inhibits Release of Glutamate and Aspartate from Slices of Hippocampal Area CA1", Eur. J. Pharmacol. (1993) 250, 473-476.
✓	SINGH, B. "The Mechanism of Action of Calcium Antagonists Relative to Their Clinical Applications", Br. J. Clin. Pharmacol. (1986) 21, 109-121.

Examiner Signature	P. Spinack	Date Considered	7/24/05
--------------------	------------	-----------------	---------

*EXAMINER If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/788,478		
		Filing Date	March 1, 2004		
		First Named Inventor	Jean-Pierre Julien		
		Art Unit	1614		
		Examiner Name	SPIVACK		
Sheet	4	of	4	Attorney Docket Number	1770-300US-1 VC/dm

ps		The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, "Tissue Plasminogen Activator For Acute Ischemic Stroke", New Eng. J. Med. (1995) 333, 1581-1587	
		TIKKA, T. et al., "Minocycline, a Tetracycline Derivative, Is Neuroprotective Against Excitotoxicity by Inhaling Activation and Proliferation of Microglia", J. Neurosci. (2001) 21, 2580-2588	
		VAN DEN BOSCH, L. et al., "Minocycline Delays Disease Onset and Mortality in a Transgenic Model of ALS", NeuroReport (2002) 13, 1067-1070	
		YRJANHEIKKI, J. et al., "A tetracycline Derivative, Minocycline, Reduces Inflammation and Protects Against Focal Cerebral Ischemia with a Wide Therapeutic Window", Proc. Natl. Acad. Sci. (1999) 96, 13496-13500	
		YRJANHEIKKI, J. et al., "Tetracyclines Inhibit Microglial Activation and are Neuroprotective in Global Brain Ischemia", Proc. Natl. Acad. Sci. (1998) 95, 15769-15774	
V		ZHU, S. et al., "Minocycline Inhibits Cytochrome c Release and Delays Progression of Amyotrophic Lateral Sclerosis in Mice", Nature (2002) 417, 74-78	

Examiner Signature	P. Spivack	Date Considered	7/24/05
--------------------	------------	-----------------	---------

*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.